In Brief: Nasalcrom new product bulletin

Nasalcrom new product bulletin: American Pharmaceutical Association booklet advises pharmacists that "cromolyn sodium in oral, parenteral and inhaled forms has a wide margin of safety" and "the risk of toxicity from an overdose is extremely low"; however, "patients should be warned that cromolyn sodium can cause transient nasal stinging, sneezing, or both immediately after administration of the drug." These effects "rarely require discontinuation of therapy." Cromolyn sodium is "well tolerated and has few precautions" and "may be useful for patients who cannot take or tolerate antihistamines and decongestants because of concomitant medical conditions or adverse effects" or in patients whose symptoms are not controlled by these types of medications. The allergy prevention and treatment product was recently purchased from Rx-to-OTC switch sponsor McNeil Consumer Products by Pharmacia & Upjohn ("The Tan Sheet" June 9, p. 2)...